ArticleInvestigational new drugs2015

Phase 1 study of the investigational Aurora A kinase inhibitor alisertib (MLN8237) in East Asian cancer patients: pharmacokinetics and recommended phase 2 dose.

Karthik Venkatakrishnan et al.PubMed ↗Publisher ↗

No numbers read from the abstract.